Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2015

01.05.2015 | Original Article

Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience

verfasst von: Mauro Borzio, Elena Dionigi, Angelo Rossini, Anna Toldi, Giampiero Francica, Fabio Fornari, Andrea Salmi, Fabio Farinati, Susanna Vicari, Massimo Marignani, Fulvia Terracciano, Barbara Ginanni, Rodolfo Sacco

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent data suggest that outcome of hepatocarcinoma is improving.

Aims

In order to explore whether survival is also increasing in clinical practice, we compared two multicenter independent in-field cohorts of cirrhotics with newly diagnosed HCCs.

Methods

Cohort 1 (C1) consisted of 327 patients enrolled between January and December 1998, and cohort 2 (C2) included 826 patients enrolled between September 2008 and November 2012. Patients were stratified according to Child-Pugh score, MELD score, and HCC staged according to TNM, BCLC systems.

Results

At baseline, C2 patients were significantly older, with more frequent comorbidities and better liver function. In C2, HCC was more frequently detected under regular ultrasound surveillance (P < 0.001), BCLC early stages were more frequent, and rates of smaller and uni/paucinodular tumors were significantly higher. Treatment of any type was more frequently offered to C2 patients (P < 0.001). Proportion of patients treated by TACE increased, and radiofrequency ablation was the most used ablative treatment. Survival rate was significantly higher in C2 being C1 and C2 survival at 1–3 years 72–25 and 75–44 %, respectively. Child-Pugh score A, BCLC stage A, single nodule, size ≤3 cm, belonging to cohort C2 and treatment per se independently predicted survival.

Conclusions

This in-field study showed a trend on improved HCC outcomes over time, which seems to be mainly due to a better presentation thanks to the wider application of surveillance and increased propensity to treat patients. These encouraging data should support further efforts to implement such approach to HCC in everyday clinical practice.
Literatur
1.
Zurück zum Zitat Bosh FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.CrossRef Bosh FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.CrossRef
2.
Zurück zum Zitat El-Seragh H. Hepatocellular carcinoma. An epidemiologic view. J Clin Gastroenterol. 2002;35:S72–S78.CrossRef El-Seragh H. Hepatocellular carcinoma. An epidemiologic view. J Clin Gastroenterol. 2002;35:S72–S78.CrossRef
3.
Zurück zum Zitat El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–65.CrossRefPubMed El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–65.CrossRefPubMed
4.
Zurück zum Zitat Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology. 2008;48:137–145.CrossRefPubMed Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology. 2008;48:137–145.CrossRefPubMed
5.
Zurück zum Zitat Capocaccia R, Sant M, Berrino F, et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007;102:1661–1670.CrossRefPubMed Capocaccia R, Sant M, Berrino F, et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007;102:1661–1670.CrossRefPubMed
6.
Zurück zum Zitat Shah SA, Smith JK, Li Y, et al. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019–1026.CrossRefPubMed Shah SA, Smith JK, Li Y, et al. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019–1026.CrossRefPubMed
7.
Zurück zum Zitat Eltekruse SF, McGlynn KA, Dickie LA, et al. Hepatocellular confirmation, treatment, and survival in surveillance, epidemiology and end results registries, 1992–2008. Hepatology. 2012;55:476–482.CrossRef Eltekruse SF, McGlynn KA, Dickie LA, et al. Hepatocellular confirmation, treatment, and survival in surveillance, epidemiology and end results registries, 1992–2008. Hepatology. 2012;55:476–482.CrossRef
8.
Zurück zum Zitat Sangiovanni E, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014.CrossRefPubMed Sangiovanni E, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014.CrossRefPubMed
9.
10.
Zurück zum Zitat El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating hepatocellular carcinoma among medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158–166.CrossRefPubMed El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating hepatocellular carcinoma among medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158–166.CrossRefPubMed
11.
Zurück zum Zitat Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.CrossRefPubMed Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.CrossRefPubMed
12.
Zurück zum Zitat Borzio M, Colloredo-Mels G, Pioltelli P, et al. Gruppo epatologico lombardo. epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011–1017.CrossRefPubMed Borzio M, Colloredo-Mels G, Pioltelli P, et al. Gruppo epatologico lombardo. epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011–1017.CrossRefPubMed
13.
Zurück zum Zitat Borzio M, Fornari F, DeSio I, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an italian field practice multicenter study. Future Oncol. 2013;9:283–294.CrossRefPubMed Borzio M, Fornari F, DeSio I, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an italian field practice multicenter study. Future Oncol. 2013;9:283–294.CrossRefPubMed
14.
15.
Zurück zum Zitat Sherman M, Bruix J, Porayko M, et al. Screening for hepatocellular carcinoma: the rationale for the American association for the study of liver diseases recommendations. Hepatology. 2012;56:793–796.CrossRefPubMed Sherman M, Bruix J, Porayko M, et al. Screening for hepatocellular carcinoma: the rationale for the American association for the study of liver diseases recommendations. Hepatology. 2012;56:793–796.CrossRefPubMed
16.
Zurück zum Zitat Bolondi L, Sofia S, Siringo S, et al. Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–259.CrossRefPubMedCentralPubMed Bolondi L, Sofia S, Siringo S, et al. Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–259.CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed
18.
Zurück zum Zitat Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed
19.
Zurück zum Zitat Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.CrossRefPubMed Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.CrossRefPubMed
20.
Zurück zum Zitat Massarweh NN, Park JO, Farjah F, et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441–448.CrossRefPubMedCentralPubMed Massarweh NN, Park JO, Farjah F, et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441–448.CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2010;52:380–388.CrossRefPubMed Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2010;52:380–388.CrossRefPubMed
22.
Zurück zum Zitat Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–89.CrossRefPubMed Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–89.CrossRefPubMed
23.
Zurück zum Zitat Pompili M, Saviano A, De Mattheis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey. J Hepatol. 2013;59:89–97.CrossRefPubMed Pompili M, Saviano A, De Mattheis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey. J Hepatol. 2013;59:89–97.CrossRefPubMed
24.
Zurück zum Zitat Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Sem Liver Dis. 1999;19:329–338.CrossRef Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Sem Liver Dis. 1999;19:329–338.CrossRef
25.
Zurück zum Zitat Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716.CrossRefPubMed Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716.CrossRefPubMed
26.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefPubMed
27.
Zurück zum Zitat Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRefPubMed Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRefPubMed
28.
Zurück zum Zitat Davila JA, Duan Z, McGlynn KA, et al. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population based study in the United States. J Clin Gastroenterol. 2012;46:71–77.CrossRefPubMed Davila JA, Duan Z, McGlynn KA, et al. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population based study in the United States. J Clin Gastroenterol. 2012;46:71–77.CrossRefPubMed
29.
Zurück zum Zitat Mirici-Cappa F, Gramenzi A, Santi V, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010;59:387–396.CrossRefPubMed Mirici-Cappa F, Gramenzi A, Santi V, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010;59:387–396.CrossRefPubMed
Metadaten
Titel
Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience
verfasst von
Mauro Borzio
Elena Dionigi
Angelo Rossini
Anna Toldi
Giampiero Francica
Fabio Fornari
Andrea Salmi
Fabio Farinati
Susanna Vicari
Massimo Marignani
Fulvia Terracciano
Barbara Ginanni
Rodolfo Sacco
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3427-5

Weitere Artikel der Ausgabe 5/2015

Digestive Diseases and Sciences 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.